XL t(14;18) IGH/BCL2

Translocation/Dual Fusion Probe

Order Number
Package Size
100 µl


XL t(14;18) IGH/BCL2

This product has been replaced by XL t(14;18) IGH/BCL2 DF. Order Number D-5113-100-OG

Clinical Details

Follicular lymphomas (FL) and diffuse large cell lymphoma (DLBCL) represent the most common entities of non-Hodgkin's lymphoma (NHL) worldwide with up to 29 % and 37 % of B-cell lymphomas.

The translocation t(14;18) juxtaposes the IGH enhancer region with the BCL-2 oncogen at 18q21 and is present in 70 % to 95 % of follicular lymphomas. By this rearrangement BCL-2 gene expression is deregulated, leading to overproduction of the antiapoptotic protein BCL-2. The same aberration is present in 20 - 30 % of diffuse large cell lymphomas.

Clinical Applications

  • Non-Hodgkin Lymphomas (NHL)


XL t(14;18) IGH/BCL2

XL t(14;18) IGH/BCL2 hybridized to lymphocytes. One normal interphase and metaphase are shown.

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange signals (2O).

Expected Pattern 2

Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange fusion signals (2GO).


  • Einerson et al (2005) Am J Clin Pathol 124:421-429
  • Weinberg et al (2007) J Mol Diagn 9:530-537
  • Gu et al (2008) Arch Pathol Lab Med 132:1355-1361


Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.